Sulforaphane, a naturally occurring compound found in cruciferous vegetables such as broccoli and Brussels sprouts, is garnering significant attention for its profound therapeutic potential against glioblastoma (GBM)—an aggressive and notoriously treatment-resistant brain tumor. Researchers have now elucidated how sulforaphane triggers cell morphology changes and apoptotic death in glioblastoma cells through the activation of endoplasmic reticulum stress (ERS) pathways, a groundbreaking discovery that could pave the way for novel interventions in GBM treatment.

Glioblastoma remains one of the most challenging cancers to treat, primarily due to its rapid progression and invasive nature. Current therapies offer limited survival benefits, emphasizing the urgent need for innovative molecularly targeted approaches. Sulforaphane’s multitargeted mechanisms, coupled with its low toxicity in normal cells, provide a tantalizing prospect for addressing these challenges by inducing selective cancer cell death.

The study reveals that sulforaphane activates the unfolded protein response (UPR), a conserved cellular stress mechanism residing in the endoplasmic reticulum (ER), which ensures protein homeostasis. Disturbances in ER function lead to accumulation of unfolded or misfolded proteins, triggering UPR signaling cascades aimed at restoring equilibrium or, if stress persists, initiating programmed cell death. This delicate balance is exploited therapeutically in glioblastoma cells through sulforaphane.

.adsslot_czWInUqsGm{ width:728px !important; height:90px !important; }
@media (max-width:1199px) { .adsslot_czWInUqsGm{ width:468px !important; height:60px !important; } }
@media (max-width:767px) { .adsslot_czWInUqsGm{ width:320px !important; height:50px !important; } }

ADVERTISEMENT

Through a series of meticulous in vitro experiments involving both primary human glioma cells and established GBM cell lines, the researchers demonstrated that sulforaphane treatment induces significant apoptotic cell death. RNA sequencing highlighted robust transcriptional changes centered around key UPR-associated genes, particularly those encoding for the transcription factors ATF4 and CHOP. These findings firmly establish the molecular underpinnings of sulforaphane’s pro-apoptotic impact within GBM cells.

Subsequent protein analyses through Western blot and immunofluorescence microscopy confirmed that sulforaphane not only upregulates but also facilitates the nuclear translocation of ATF4 and CHOP, which are pivotal effectors mediating ER stress-induced apoptosis. CHOP, in particular, is a well-characterized pro-apoptotic transcription factor whose increased expression sensitizes cancer cells to stress-mediated death pathways.

To validate the causative role of CHOP in mediating sulforaphane’s cytotoxicity, the researchers applied a CHOP knockdown approach. The attenuation of apoptosis in CHOP-silenced GBM cells underscored CHOP’s indispensable role as a molecular switch in sulforaphane-induced cell death, highlighting the therapeutic importance of targeting this axis within the UPR pathway.

Further supporting the significance of ER stress in sulforaphane’s activity, the study employed 4-phenylbutyrate (4-PBA), a chemical chaperone known to alleviate ER stress. Treatment with 4-PBA markedly reduced sulforaphane-induced apoptosis, thereby reaffirming that the antitumor effects hinge critically on ER stress activation and UPR signaling rather than off-target toxicities.

Importantly, in contrast to its potent effects on GBM cells, sulforaphane exhibited minimal cytotoxicity against normal human astrocytes—the supportive glial cells in the brain—indicating a favorable therapeutic window. This selectivity reduces concerns about neurotoxicity and enhances sulforaphane’s feasibility as a candidate for clinical development.

Translating these findings into an in vivo context, the research team utilized an intracranial glioma xenograft mouse model to examine sulforaphane’s efficacy. Treated animals exhibited significantly reduced tumor burden, accompanied by elevated markers of ER stress within tumor tissues, validating the compound’s capability to engage the UPR pathway and induce apoptosis in a physiological brain tumor milieu.

This comprehensive investigation sheds light on a previously underappreciated mechanism through which sulforaphane exerts antitumor activity—via the ATF4–CHOP axis within the UPR. By pushing glioblastoma cells beyond adaptive survival mechanisms and into apoptotic pathways, sulforaphane effectively disrupts tumor persistence and progression.

Given that current glioblastoma treatments are hampered by drug resistance and off-target effects, the potential for sulforaphane to modulate intrinsic cellular stress responses without harming normal brain cells is particularly compelling. These insights open avenues for combination therapies that might enhance efficacy or overcome resistance by synergizing with ER stress inducers.

The study’s molecular dissection of sulforaphane’s impact highlights the therapeutic promise of modulating ER stress and protein homeostasis pathways in cancer—a paradigm that could extend beyond glioblastoma to other solid tumors characterized by proteostasis dysregulation.

Moreover, sulforaphane’s origin as a dietary phytochemical found naturally in vegetables further underscores the potential for integrating nutraceutical approaches with conventional oncology therapies, offering patients safer and potentially more effective treatment regimens.

As researchers continue to decode the intricate relationships between cellular stress responses and cancer, the sulforaphane-ERS axis delineated here stands as a beacon of hope. Future clinical investigations will be critical to assess the pharmacokinetics, dosing strategies, and combinatorial regimens that can harness this pathway for maximal therapeutic benefit.

In conclusion, this landmark study positions sulforaphane as a promising multitargeted agent capable of inducing glioblastoma cell apoptosis through activation of ER stress and the unfolded protein response, particularly via ATF4 and CHOP. Such mechanistic unraveling not only enriches our understanding of cancer biology but also propels us closer to innovative, precise therapies against one of the deadliest brain cancers.

Subject of Research:
Glioblastoma treatment mechanisms focused on sulforaphane-induced apoptosis via endoplasmic reticulum stress pathways.

Article Title:
Sulforaphane induces cell morphology change and cell apoptosis by activating endoplasmic reticulum stress in glioblastoma.

Article References:
Li, N., Jiang, Y., Wang, A. et al. Sulforaphane induces cell morphology change and cell apoptosis by activating endoplasmic reticulum stress in glioblastoma. BMC Cancer 25, 1050 (2025). https://doi.org/10.1186/s12885-025-14378-4

Image Credits:
Scienmag.com

DOI:
https://doi.org/10.1186/s12885-025-14378-4

Tags: apoptosis in cancer cellsendoplasmic reticulum stress pathwaysglioblastoma treatment resistanceinnovative approaches to brain tumorslow toxicity cancer treatmentsmolecularly targeted cancer interventionsmultitargeted cancer therapiesprotein homeostasis in glioblastomaselective cancer cell death mechanismssulforaphane and glioblastomatherapeutic potential of cruciferous vegetablesunfolded protein response activation